Investigators recently inspected the company’s facility and found poor sterile production practices, which resulted in the initial product alert. This week that alert was expanded.
The agency has not learned of any adverse events from improperly sterilized NuVision products. The alert is cautionary.
More Articles on Anesthesia:
FDA Changes Label, Lowers Dose Recommendation for Zolpidem Insomnia Drug
Masimo Announces Clinical Study Outcomes at International Anesthesia Research Society Meeting
Physician Office Partners Releases Billing Solution for Anesthesia Practices
